Early, Late-Stage, and metastatic kidney cancer options are one call away
Call Now
Early, Late-Stage, and Metastatic Kidney Cancer Treatment Options
Helping Patients Outperform Kidney Cancer Statistics with
Powerful New Treatment Options
A kidney cancer diagnosis can be a life changing experience, but Envita Medical Centers provides personalized
treatment
options that go beyond standardized clinical oncology to help prevent our patients from becoming a statistic. At
Envita
Medical Centers, a world-class integrative center for Precision Oncology, we use a powerful combination of targeted
therapies, including the latest in conventional as well as research-based natural and alternative medicines, to aid
patients in progression towards disease-free survival and improving their quality of life.
In our clinical oncology experience of over 20 years, advanced kidney cancer treatments administered with precision
immunotherapy options has been a game changer in helping patients respond to care, even those left with only
palliative
care options at major cancer centers in the country. Our proprietary new treatments, such as CIPI™ (Chemo Immuno
Precision Injections) and GTFC™ (Genetically Targeted Fractionated Chemotherapy), utilize a combination of genetically
targeted precision options with customized immunotherapies to treat patients of all stages, including stage I to stage
IV.
Our personalized N of 1 level of care has benefitted patients with
several types of complicated and advanced kidney cancers, such as renal cell carcinoma (RCC), urothelial carcinoma,
clear cell kidney cancers, and chromophobes.
Our treatment options follow the N of 1 approach, which allows us to personalize treatment
for each
kidney cancer patient. Personalization is extremely crucial when tackling a disease like cancer because it
is caused by
genetic mutations, and genetics vary from person to person.
This article covers basic facts about kidney cancer, including:
Hear from Maria Brougham, a renal cell carcinoma survivor who is cancer-free now, despite getting a stipulated time
to live by her standard oncology providers
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
How Envita Overcomes Standard Kidney Cancer Treatment and Clinical Trial Challenges
Standard kidney cancer treatments, such as partial nephrectomy (removal of a part of the kidney), radical nephrectomy
(removal of the whole kidney, along with the adrenal gland at times), radiation therapy, systemic therapies like
immunotherapy, targeted therapy, and chemotherapy, may be helpful for some patients but they are missing a key aspect
for long-term success, personalization!
None of these treatment options are personalized to the level that Envita provides to attack the cancer drivers of
each
individual patient. These standard treatments, followed at all major cancer centers across the country, are generally
based on the NCCN
(National Comprehensive Cancer Network) guidelines, which do not allow personalization as a first-line treatment.
The absence of personalization in the standard first-line treatment explains why patients with the same stage and
type
of cancer do not respond similarly to the same treatment. To overcome these challenges, Envita personalizes its
precision oncology treatments for each individual patient, which enhances treatment efficacy and reduces chances of
metastasis.
According to the American Cancer Society’s report based on patient outcomes across standard cancer centers,
typically
following the NCCN guidelines, the 5-year relative survival
rate of kidney cancer drops down to 14% when the disease spreads to distant parts of the body.
Envita Medical Centers Medical Team
Physicians with MD, MD(h), and NMD medical
licenses, including certified oncologists, and certified interventional radiologists,
striving to provide the latest cancer innovations
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+
A Personalized Plan May Be More Effective Than Clinical Trials
Ongoing clinical trials to test new treatments in kidney cancer are often recommended for early stage as well as
late-stage patients, but all patients should approach with
caution as these trials may not be equally effective for everyone. The goal of a clinical trial is to test the
efficacy of a new
treatment based on the response of the majority of its patients, which does not focus on each individual patient’s
unique set of genetic mutations. On the other hand, Envita’s personalized precision oncology treatment plan aims to
address all the risk factors responsible for each individual patient’s kidney cancer, potentially improving their
chances of a favorable outcome.
Envita’s New Treatments and Their Effects on Patient Outcomes
Envita breaks the mold of standard healthcare NCCN treatments to potentially improve outcomes in kidney cancer
patients.
It goes beyond NCCN’s one-size-fits-all treatments based on the stage and type of cancer to impact the unique set of
genetic mutations responsible for the cause and spread of kidney cancer in each individual patient.
We have been able to help several patients, even those with inoperable tumors, live a long, healthy, and superior
quality life, without having to deal with the side effects of surgeries or surgical removal of kidneys. According to
medical
studies, the rates of chronic kidney disease (CKD) in patients who have undergone nephrectomy might be higher.
The risks of
new-onset or accelerated CKD and worsened survival after nephrectomy might be linked, as kidney insufficiency is a
risk
factor for cardiovascular disease and mortality.
To mitigate such risks and avoid dependency on routine dialysis or a kidney transplant, we personalize our treatments
and attack each patient’s unique cancer diagnosis from all possible angles. Our personalized and minimally invasive
treatments are designed to reduce chances of metastasis in early stages, while in later stages, such as advanced renal
cell carcinomas, these treatments may potentiate better outcomes by directly affecting each patient’s unique set of
genetic mutations.
Envita Medical Centers’ personalized precision oncology approach follows a 4-step process to design an exclusive
medical
blueprint for each individual patient, which takes into account their unique set of mutations. This personalized
medical
blueprint is aimed at optimizing quality of life, increasing longevity, and reducing toxicity.
Step 1
Genomic Identification Attacks Cancer at Its Root and Helps Check Metastasis
Approximately one-third of patients with renal cell carcinoma (RCC) present with metastatic disease, and amongst
those
patients with localized disease, a substantial proportion will recur. To check such
recurrences and metastases, every patient needs a detailed genomic
identification, which is crucial for developing a comprehensive treatment plan. However, not everyone gets
access to genomic analysis,
which is considered a part of precision oncology, in standard NCCN guided cancer treatment centers.
At Envita, Every Patient’s Treatment Plan Is Built on a Detailed Genomic Analysis!
The NCCN guidelines allow access to precision oncology as a follow-up to failed first-line treatments, but this delay
may be disastrous in a life-threatening condition. Even the handful of patients who get access to precision oncology
in
standard cancer treatment centers receive a watered-down version of our detailed precision kidney cancer treatment
offerings.
Envita’s Proprietary Testing Analyses Many More
Parameters Than Other Cancer Centers!
Envita Precision Algorithm vs. Standard Oncology Precision Testing
Envita Medical Centers
Standard Oncology Precision Testing
RNA Transcriptome Genes
Envita Medical Centers:20,000+
Standard Oncology:Unchecked
SNV/CNV Genes
Envita Medical Centers:452
Standard Oncology:309
Rearrangements/Fusion Genes
Envita Medical Centers:51
Standard Oncology:27
Microsatellite Instability (MSI)
Envita Medical Centers:Checked
Standard Oncology:Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers:Checked
Standard Oncology:Checked
BRCA 1/2
Envita Medical Centers:Checked
Standard Oncology:Checked
Immunohistochemistry
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Chemosensitivity
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Exosomal miRNA Analysis
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Pharmacogenomics
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Individualized Therapy Recommendation
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Inflammation Markers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Metabolic Target Drivers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Genetic mutations causing cancer may be triggered by hereditary or environmental factors, which is why an exhaustive
analysis is crucial to seek the most appropriate anti-cancer agents for each individual patient. This analysis enables
us to intensify the attack against kidney cancer and potentially improve patient outcomes, as we use anti-cancer
agents
with the highest probability of impacting each patient’s unique set of mutations.
Step 2
Immuno Targeting Strengthens Your Immune System to Effectively Fight Against Cancer
Immunotherapy and targeted therapy are either considered first-line treatments for kidney cancer or utilized as
adjuvant
therapies after nephrectomies. At Envita, we enhance the efficacy of these treatments by personalizing them to suit
each
individual patient, based on immuno targeting via our Ultra Analytes Liquid Biopsy.
Genetic mutations causing cancer may be triggered by hereditary or environmental factors, which is why an exhaustive
analysis is crucial to seek the most appropriate anti-cancer agents for each individual patient. This analysis enables
us to intensify the attack against kidney cancer and potentially improve patient outcomes, as we use anti-cancer
agents
with the highest probability of impacting each patient’s unique set of mutations.
Envita’s
Ultra Analytes Liquid Biopsy is a key component in
creating your
personalized treatment plan.
This proprietary liquid biopsy enables us to identify and proactively treat metastasis, by examining the Circulating
Tumor Cells (CTCs) in a patient’s blood stream. A simple blood draw helps in collecting CTCs, which break away from a
growing tumor and enter a patient’s bloodstream, spreading the cancer to other parts of the body. The CTC analysis
throws light on the latest genetic mutations, equipping us to proactively treat the disease and reduce chances of a
metastatic spread.
Missing out on this aspect of treatment explains why many patients undergoing standard treatment may experience
cancer
recurrence and metastases, despite partial or radical nephrectomies. Our personalized next level
immunotherapies and targeted therapies established through immuno targeting are designed to overcome such
challenges.
Immunotherapy
Immunotherapy is used to harness the power of your immune system in effectively impacting your cancerous cells, but
patients may not always respond to the standard immunotherapy drugs such as PD-1, PD-L1, and CTLA-4 checkpoint
inhibitors and cytokines like interleukin-2 and interferons, due to their weakened immunity. At Envita, we understand
the importance of bolstering your immune system to help enhance the efficacy of these drugs, which is why we have
published a scientific study on “Immunotherapy in Cancer Treatment.”
This study draws from our innovative research and extensive clinical experience in the field of immunotherapy and
discusses about the various forms of cancer vaccines as an important aspect in immunotherapy.
In fact, a study about “Therapeutic
challenges in renal cell carcinoma indicates the importance of developing patient individualized tumor vaccines
specific to patient tumor antigens, which
is exactly what we strive to do here at Envita. Customizing different immunotherapies and combining them with targeted
therapies may help even in advanced stages when patients are left with limited standard treatment options.
Targeted Therapy
A recent study published in the New
England
Journal of Medicine established that progression-free survival was significantly longer
when a combination of immunotherapy and targeted therapy drugs were administered to patients with previously untreated
advanced renal cell carcinoma with a clear cell component. Targeted therapy drugs are meant to affect only the
cancer’s
specific genes, proteins, or the tissue environment that contributes to disease growth and survival, without damaging
the surrounding healthy cells.
However, at Envita our entire treatment approach is precision-targeted to intensify the attack on cancerous cells
while
reducing chances of side effects. Even our chemotherapies called GTFC™
(Genetically Targeted Fractionated Chemotherapy) work on this principle, utilizing a low dose of anti-cancer agents
which are precision targeted to maximize impact on the cancerous cells. GTFC™ may be used as an adjuvant therapy in
certain kidney cancer cases, along with other forms of targeted therapy.
Our targeted therapies go way beyond the standard anti-angiogenesis therapy, Tyrosine Kinase Inhibitors (TKIs),
and
mTOR
inhibitors, to deactivate kidney tumors and prevent cancer spread. A tumor grows by recruiting blood vessels
around
it
through the process of angiogenesis. These blood vessels carry essential nutrients required for the tumor to grow,
and
certain proteins such as the vascular endothelial growth factor (VEGF), tyrosine kinases, and mTOR, can stimulate
this
process of blood vessel formation.
To check angiogenesis, the VEGF protein is blocked either with small molecule inhibitors of the VEGF receptors or
with
antibodies directed against these receptors, while tyrosine kinase and mTOR are blocked with their respective
inhibitors. However, Envita’s cutting-edge targeted therapies delve much deeper than VEGF and other proteins to
explore
the molecular cell biology of each individual patient and comprehensively treat their kidney cancer.
Here are certain factors, examined via our detailed gnomic analysis, to guide the development of our personalized
targeted therapies:
Genomics Analyzing DNA alterations that can affect the structure, function, and number of corresponding
proteins
produced by cells.
Transcriptomics: Examining the miRNA (MicroRNA), which includes tumor suppressor genes and oncogenes, as
an over production of the latter causes uncontrolled cell growth, prevents apoptosis, and spreads the cancer.
Proteomics: Investigating all the differently expressed proteins in cancerous cells, as compared to their
healthy counterparts.
Metabolomics: Probing cancer cell metabolites which provide pathways and signaling information to support
disease
proliferation.
Microsatellite Instability (MSI): Microsatellite Instability (MSI) is the result of mutations that do not
get corrected when DNA is copied inside of a cell, allowing for continued mutations of cancerous cells, making
treatment difficult. Overcoming the mutational rate of cancer is essential to impact this genetic disease and
improve outcomes, which is why we focus on analyzing MSI.
Epigenetic Influences on Mutation: Epigenetic influences can cause mutations in proto-oncogenes, which are
genes that normally help cells grow, and transform them into oncogenes, a type of miRNA. At Envita, we utilize
personalized miRNA gene silencing therapies to treat the disease down to its cellular level and reduce chances of
further tumor growth and metastasis.
Step 3
Personalized Drug Design Enhances Treatment Efficacy
Every new kidney cancer drug may not always work for all affected patients. A
2021
study states that with newer drugs for patients with kidney cancer, it is important to understand that
these drugs may not
work in every patient and instead may expose patients to unnecessary toxic effects.
To counter such side effects and enhance the efficacy of newer drugs for each patient, we custom-compound
adjuvants at
our in-house
pharmacy. These
adjuvants are based on advanced phytotherapeutics, including a powerful blend of plant extracts and herbs.
FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.
In our clinical opinion, a combination of FDA (Food and Drug Administration) approved drugs, repurposed drugs, and
custom-compounded adjuvants, helps in not only attacking the cancerous cells but also rebuilding patients’ immune
systems. This personalized
drug design approach
boosts the body’s innate ability to effectively strike against cancer, minimizing chances of a recurrence or
metastatic spread.
Step 4
Precision Deployment of Proprietary New Treatments Target Tumor Cells, Potentially Reducing Side Effects
At Envita, we utilize several leading-edge therapies in combination with our proprietary new treatments, which are
precision deployed to deactivate the tumors, without damaging the surrounding healthy cells. With the healthy cells
remaining intact, patients rarely ever experience side effects, such as fatigue, kidney damage, fluid in the lungs, or
other problems associated with standard kidney cancer treatments.
Envita’s Precision Oncology Provides Important Quality of Life Metrics
88%*of patients reported symptom score improvement under Envita Medical
Centers’ Care
95%*fewer side-effects are experienced by patients receiving precision
oncology at Envita Medical Centers
Some of our different treatment options for kidney cancer are as follows:
CIPI™ (Chemo Immuno Precision Injections)
CIPI™ is our proprietary interventional radiology
procedure for tumor embolization. As part of this procedure, a tiny catheter
is used to carry genetically targeted chemo and immuno agents directly to the affected site, causing tumor necrosis
and
a systemic response throughout the body. This direct delivery of genetically targeted medications has been beneficial
for several patients who are unable to go through surgeries, for several reasons.
Envita's CIPI™ vs. Standard Surgery
Envita Medical Centers
Standard Surgery
Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical
incisions.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op
complications.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a
medically induced coma to perform an invasive surgery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other
metastatic cancer sites in the body.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of
hospital stays for recovery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Cryoablation
In the case of small kidney tumors, patients may have to stay under active surveillance, where the tumor is watched
closely via CT scans, or go through a cryoablation procedure. This minimally invasive procedure utilizes extreme cold
to
kill cancerous cells. A hollow needle carrying cold gases is image-guided directly into the tumor to necrose it, but
at
Envita we backup this procedure with personalized immunotherapy to reduce chances of lesions or tumor growth in the
future.
RFA (Radiofrequency Ablation)
OsteoCool™ RF Ablation is a leading, innovative technology that allows your doctor to deliver the radiofrequency
ablation to the precise location of your tumor, avoiding impact on surrounding areas. This proprietary radiofrequency
ablation procedure uses alternating, low-power current to generate heat. In order to ablate (completely destroy) the
cancerous cells, this heat is delivered by a probe directly to the tumor to intentionally dry out and kill the
cancerous
cells. During the procedure, pumped water circulates through the probes to cool the temperature and reduce damage to
the
area. This effective RFA procedure is predictable, minimally invasive, and helps reduce pain and radiation exposure.
Types and Sub-Types of Kidney Cancer
Kidney cancer is divided into types and sub types depending on the site of origin of the tumors and the type of
cells it comprises. They are as follows:
Renal Cell Cancer (without or with Sarcomatoid features, which are responsible for making the cancer more
aggressive)
develops in the renal tubules that make up the kidney’s filtration system. If this cancer spreads beyond the kidneys
to
distant lymph nodes or other parts of the body, then it is called metastatic renal cell carcinoma.
Clear cell: The vast majority of kidney cancers are made up of clear cells, making this a common
subtype.
Papillary: One of the rare sub types of kidney cancer, which may be localized or metastatic.
Chromophobe: Another uncommon subtype which does not usually spread, but may turn aggressive in certain
cases.
Sarcoma: Develops in the soft tissues of the kidney.
Wilms Tumor: Is a rare form of kidney cancer, commonly seen in children.
Lymphoma: Is classified as secondary renal lymphoma (SRL) when kidneys are enlarged due to cancer in the
lymph nodes in
other parts of the body, and primary renal lymphoma (PRL) when there is a lone tumor mass in the kidney with
potentially
enlarged regional lymph nodes.
Collecting Duct Carcinoma: Begins in the area where urine collects in the kidneys before moving to the
bladder. It is
closely related to transitional cell carcinoma, also called urothelial carcinoma.
Renal Medullary Carcinoma: Is a rare but highly aggressive cancer of the kidney that usually affects people
carrying
sickle cell disease.
Oncocytoma: Is usually a benign tumor made of oncocytes, a type of cell.
Angiomyolipoma: Is another type of benign tumor, which may be asymptomatic or trigger symptoms like fever,
high blood pressure, or
anemia.
Risk Factors for Kidney Cancer
Certain factors cause a high risk of kidney cancer, which is why managing some of the following triggers may serve
as a preventive measure:
Smoking
Obesity
High blood pressure
Long-term exposure to certain pain medications
Family history of kidney cancer
Affected with conditions such as von Hippel-Lindau disease
Our oncologists are specially trained in the personalized precision oncology approach for over
1,500 hours. They work relentlessly to uproot the disease and help patients progress in their journey towards a
holistic recovery. If you or a loved one have any questions about kidney cancer or any other cancers, please do not
hesitate to call us at: 866-830-4576. We are looking forward to hearing from you. May God bless you on your journey
to healing!
* Data is based on our analysis of records for 87 out of 129 patients that participated in
* The 3rd party actuarial response data is based on an analysis of records for 87 out of 129 patients that
participated
in Envita’s Treatment Program in 2020. 42 patients were removed from the cohort due to the patients’ inability to
start
or complete Envita’s prescribed treatment for a variety of reasons, including but not limited to, advanced disease
state, disease progression, or inability to travel.
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
